Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma

Emilio Bajetta, Laura Catena, Pamela Biondani, Sara Pusceddu, Monica Valente, Nadia Bianco, Eugenio Novelli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aim: No standard treatment has been established for poorly-differentiated neuroendocrine carcinomas (PDNEC). The aim of this study is to evaluate the response to the combination of three drugs. Material and Methods: We reviewed 21 PDNEC patients treated from 2008 to 2013 in two Institutions. Five patients were initially treated with epirubicin, fluorouracil and temozolomide. Because of toxicity, the regimen was modified into cisplatin, capecitabine and dacarbazine (scheme B-CLOVER regimen). Results: Primary tumor site was: pancreas 7 (33%), lung 5 (24%), colon-rectum 5 (24%), unknown 3 (14%) and stomach 1 (5%). The response rate was 24% (0 complete response, 24% partial responses, 38% stable disease, 9% progression and 19% unassessable). The global overall survival (OS) is 13 months (range=1-29) and progression-free survival (PFS) was 6 months (range=1-11). Conclusion: The combination chemotherapy of cisplatinum, capecitabine and dacarbazine is feasible and should be considered as an option for PDNEC.

Original languageEnglish
Pages (from-to)5657-5660
Number of pages4
JournalAnticancer Research
Volume34
Issue number10
Publication statusPublished - Oct 1 2014

Fingerprint

Neuroendocrine Carcinoma
Drug Combinations
Cisplatin
Dacarbazine
temozolomide
Epirubicin
Combination Drug Therapy
Rectum
Fluorouracil
Disease-Free Survival
Disease Progression
Pancreas
Stomach
Colon
Lung
Survival
Neoplasms
Capecitabine
Therapeutics

Keywords

  • Chemotherapy
  • PDNEC
  • Poorly-differentiated neuroendocrine carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Bajetta, E., Catena, L., Biondani, P., Pusceddu, S., Valente, M., Bianco, N., & Novelli, E. (2014). Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma. Anticancer Research, 34(10), 5657-5660.

Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma. / Bajetta, Emilio; Catena, Laura; Biondani, Pamela; Pusceddu, Sara; Valente, Monica; Bianco, Nadia; Novelli, Eugenio.

In: Anticancer Research, Vol. 34, No. 10, 01.10.2014, p. 5657-5660.

Research output: Contribution to journalArticle

Bajetta, E, Catena, L, Biondani, P, Pusceddu, S, Valente, M, Bianco, N & Novelli, E 2014, 'Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma', Anticancer Research, vol. 34, no. 10, pp. 5657-5660.
Bajetta, Emilio ; Catena, Laura ; Biondani, Pamela ; Pusceddu, Sara ; Valente, Monica ; Bianco, Nadia ; Novelli, Eugenio. / Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma. In: Anticancer Research. 2014 ; Vol. 34, No. 10. pp. 5657-5660.
@article{87a8230892ce43f6820b316be6080895,
title = "Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma",
abstract = "Background/Aim: No standard treatment has been established for poorly-differentiated neuroendocrine carcinomas (PDNEC). The aim of this study is to evaluate the response to the combination of three drugs. Material and Methods: We reviewed 21 PDNEC patients treated from 2008 to 2013 in two Institutions. Five patients were initially treated with epirubicin, fluorouracil and temozolomide. Because of toxicity, the regimen was modified into cisplatin, capecitabine and dacarbazine (scheme B-CLOVER regimen). Results: Primary tumor site was: pancreas 7 (33{\%}), lung 5 (24{\%}), colon-rectum 5 (24{\%}), unknown 3 (14{\%}) and stomach 1 (5{\%}). The response rate was 24{\%} (0 complete response, 24{\%} partial responses, 38{\%} stable disease, 9{\%} progression and 19{\%} unassessable). The global overall survival (OS) is 13 months (range=1-29) and progression-free survival (PFS) was 6 months (range=1-11). Conclusion: The combination chemotherapy of cisplatinum, capecitabine and dacarbazine is feasible and should be considered as an option for PDNEC.",
keywords = "Chemotherapy, PDNEC, Poorly-differentiated neuroendocrine carcinoma",
author = "Emilio Bajetta and Laura Catena and Pamela Biondani and Sara Pusceddu and Monica Valente and Nadia Bianco and Eugenio Novelli",
year = "2014",
month = "10",
day = "1",
language = "English",
volume = "34",
pages = "5657--5660",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma

AU - Bajetta, Emilio

AU - Catena, Laura

AU - Biondani, Pamela

AU - Pusceddu, Sara

AU - Valente, Monica

AU - Bianco, Nadia

AU - Novelli, Eugenio

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Background/Aim: No standard treatment has been established for poorly-differentiated neuroendocrine carcinomas (PDNEC). The aim of this study is to evaluate the response to the combination of three drugs. Material and Methods: We reviewed 21 PDNEC patients treated from 2008 to 2013 in two Institutions. Five patients were initially treated with epirubicin, fluorouracil and temozolomide. Because of toxicity, the regimen was modified into cisplatin, capecitabine and dacarbazine (scheme B-CLOVER regimen). Results: Primary tumor site was: pancreas 7 (33%), lung 5 (24%), colon-rectum 5 (24%), unknown 3 (14%) and stomach 1 (5%). The response rate was 24% (0 complete response, 24% partial responses, 38% stable disease, 9% progression and 19% unassessable). The global overall survival (OS) is 13 months (range=1-29) and progression-free survival (PFS) was 6 months (range=1-11). Conclusion: The combination chemotherapy of cisplatinum, capecitabine and dacarbazine is feasible and should be considered as an option for PDNEC.

AB - Background/Aim: No standard treatment has been established for poorly-differentiated neuroendocrine carcinomas (PDNEC). The aim of this study is to evaluate the response to the combination of three drugs. Material and Methods: We reviewed 21 PDNEC patients treated from 2008 to 2013 in two Institutions. Five patients were initially treated with epirubicin, fluorouracil and temozolomide. Because of toxicity, the regimen was modified into cisplatin, capecitabine and dacarbazine (scheme B-CLOVER regimen). Results: Primary tumor site was: pancreas 7 (33%), lung 5 (24%), colon-rectum 5 (24%), unknown 3 (14%) and stomach 1 (5%). The response rate was 24% (0 complete response, 24% partial responses, 38% stable disease, 9% progression and 19% unassessable). The global overall survival (OS) is 13 months (range=1-29) and progression-free survival (PFS) was 6 months (range=1-11). Conclusion: The combination chemotherapy of cisplatinum, capecitabine and dacarbazine is feasible and should be considered as an option for PDNEC.

KW - Chemotherapy

KW - PDNEC

KW - Poorly-differentiated neuroendocrine carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84917706022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917706022&partnerID=8YFLogxK

M3 - Article

C2 - 25275070

AN - SCOPUS:84917706022

VL - 34

SP - 5657

EP - 5660

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -